Potential Breakthrough for Aligos Therapeutics in Hepatitis B Treatment
AI Prediction of Aligos Therapeutics, Inc. (ALGS)
Aligos Therapeutics, focused on liver and viral diseases, is nearing key Phase 2 interim analysis for its lead asset, ALG-000184, targeting chronic hepatitis B. Positive trial outcomes could significantly impact its stock value.
Aligos Therapeutics, a clinical-stage biopharmaceutical company, is at a pivotal stage with its lead asset, ALG-000184, a potential first-/best-in-class therapy for chronic hepatitis B virus (HBV) infection. The company is preparing for interim analyses from its global Phase 2 B-SUPREME study in 1H and 2H 2026. These milestones are critical as they will provide early insights into the efficacy and safety of ALG-000184, potentially setting the stage for advanced clinical trials and strategic partnerships. The market for HBV treatments is substantial, underscoring significant commercial potential for effective therapies. Investors should closely monitor these developments, as positive data could lead to substantial share price appreciation.
ALGS Report Information
Prediction Date2026-03-27
Close @ Prediction$7.04
Mkt Cap36m
IPO DateN/a
AI-derived Information
Recent News for ALGS
- May 13, 2:05 am — Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026 (GlobeNewswire)
- May 7, 4:05 pm — Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results (GlobeNewswire)
- Apr 30, 4:05 pm — Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 (GlobeNewswire)
- Apr 24, 8:00 am — Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Apr 17, 6:54 am — Aligos and Xiamen Amoytop sign deal for HBV therapy (Pharmaceutical Technology)
- Apr 16, 6:00 am — Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection (GlobeNewswire)
- Apr 14, 4:05 pm — Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation (GlobeNewswire)
- Mar 5, 8:00 am — Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
- Feb 26, 8:00 am — Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026 (GlobeNewswire)
- Feb 23, 8:00 am — Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) (GlobeNewswire)
- Jan 30, 8:00 am — Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Jan 21, 8:00 am — Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest